<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Viva Biotech Holdings — News on 6ix</title>
<link>https://6ix.com/company/viva-biotech-holdings</link>
<description>Latest news and press releases for Viva Biotech Holdings on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 15:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/viva-biotech-holdings" rel="self" type="application/rss+xml" />
<item>
<title>Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up</title>
<link>https://6ix.com/company/viva-biotech-holdings/news/viva-biotech-announces-2025-annual-results-ai-driven-drug-discovery-reinforces-industry-leadership-cdmo-commercial-products-enter-rapid-scale-up</link>
<guid isPermaLink="true">https://6ix.com/company/viva-biotech-holdings/news/viva-biotech-announces-2025-annual-results-ai-driven-drug-discovery-reinforces-industry-leadership-cdmo-commercial-products-enter-rapid-scale-up</guid>
<pubDate>Mon, 30 Mar 2026 15:01:00 GMT</pubDate>
<description>On March 30, 2026, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue amounted to RMB1,729.4 million during the Reporting Period, with gross profit of RMB655.6 million. The Group's gross profit margin was 37.9%, representing an increase of 3.3 percentage points compared with the same period last year, mainly attributable to the optimization and adjustment of Langhua Pharmaceutical's business mix, improved operational e</description>
</item>
<item>
<title>Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities</title>
<link>https://6ix.com/company/viva-biotech-holdings/news/adventures-in-dmpk-viva-biotechs-one-stop-pharmacology-platform-cross-new-modalities</link>
<guid isPermaLink="true">https://6ix.com/company/viva-biotech-holdings/news/adventures-in-dmpk-viva-biotechs-one-stop-pharmacology-platform-cross-new-modalities</guid>
<pubDate>Mon, 29 Dec 2025 06:13:00 GMT</pubDate>
<description>Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology platform that covers this end-to-end modality range, supporting programs from in vitro ADME assays through in vivo PK and efficacy studies. Adventures in DMPK: From Small Molecules and PROTACs to Peptides and Antibodies, the latest session in the</description>
</item>
<item>
<title>Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.</title>
<link>https://6ix.com/company/viva-biotech-holdings/news/viva-biotechs-invested-and-incubated-company-arthrosi-has-entered-into-an-acquisition-agreement-with-sobi-for-a-total-transaction-value-of-up-to-usdollar15-billion</link>
<guid isPermaLink="true">https://6ix.com/company/viva-biotech-holdings/news/viva-biotechs-invested-and-incubated-company-arthrosi-has-entered-into-an-acquisition-agreement-with-sobi-for-a-total-transaction-value-of-up-to-usdollar15-billion</guid>
<pubDate>Mon, 15 Dec 2025 06:06:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first h</description>
</item>
<item>
<title>Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry</title>
<link>https://6ix.com/company/viva-biotech-holdings/news/viva-biotech-receives-frost-and-sullivans-2025-apac-technology-innovation-leadership-recognition-in-the-integrated-intelligent-drug-discovery-industry</link>
<guid isPermaLink="true">https://6ix.com/company/viva-biotech-holdings/news/viva-biotech-receives-frost-and-sullivans-2025-apac-technology-innovation-leadership-recognition-in-the-integrated-intelligent-drug-discovery-industry</guid>
<pubDate>Mon, 29 Sep 2025 09:00:00 GMT</pubDate>
<description>Viva Biotech announced today that it has been honored with Frost & Sullivan's 2025 APAC Technology Innovation Leadership recognition in the Integrated Intelligent Drug Discovery industry. As Frost & Sullivan's top honor, the award recognizes outstanding achievements in driving transformative efficiencies in preclinical research and development. It highlights Viva Biotech's consistent leadership in combining artificial intelligence (AI) with laboratory-driven validation to reshape the future of d</description>
</item>
<item>
<title>Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights</title>
<link>https://6ix.com/company/viva-biotech-holdings/news/unlocking-the-potential-of-cyclic-peptide-therapeutics-viva-biotechs-discovery-insights</link>
<guid isPermaLink="true">https://6ix.com/company/viva-biotech-holdings/news/unlocking-the-potential-of-cyclic-peptide-therapeutics-viva-biotechs-discovery-insights</guid>
<pubDate>Tue, 02 Sep 2025 09:52:00 GMT</pubDate>
<description>Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the structural advantages of biologics—making them ideally suited to address traditionally "undruggable" protein–protein interactions and complex receptors, while opening new avenues for oral drug di</description>
</item>
<item>
<title>Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth</title>
<link>https://6ix.com/company/viva-biotech-holdings/news/viva-biotech-announces-its-2025-interim-results-cro-revenue-returned-to-positive-growth-new-cdmo-commercialization-projects-showed-promising-growth</link>
<guid isPermaLink="true">https://6ix.com/company/viva-biotech-holdings/news/viva-biotech-announces-its-2025-interim-results-cro-revenue-returned-to-positive-growth-new-cdmo-commercialization-projects-showed-promising-growth</guid>
<pubDate>Thu, 28 Aug 2025 10:46:00 GMT</pubDate>
<description>On August 28, 2025, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue amounted to RMB831.9 million, and the Group's gross profit of RMB339.4 million. The Group's gross profit margin was 40.8%, an increase of 6.3 percentage points from the corresponding period of last year, primarily attributable to the optimization and adjustment of Langhua's business structure, improved operational efficiency in CRO business, and c</description>
</item>
<item>
<title>Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection</title>
<link>https://6ix.com/company/viva-biotech-holdings/news/viva-biotechs-wholly-owned-subsidiary-langhua-pharmaceutical-successfully-passes-us-fda-on-site-inspection</link>
<guid isPermaLink="true">https://6ix.com/company/viva-biotech-holdings/news/viva-biotechs-wholly-owned-subsidiary-langhua-pharmaceutical-successfully-passes-us-fda-on-site-inspection</guid>
<pubDate>Fri, 28 Mar 2025 07:46:00 GMT</pubDate>
<description>Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration ("FDA"), and received the EIR (Establishment Inspection Report) from the FDA. This is the fourth time that Langhua Pharmaceutical has undergone and passed the on-site inspection by the FDA, indicating the effective operation of the Company's qua</description>
</item>
<item>
<title>Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D</title>
<link>https://6ix.com/company/viva-biotech-holdings/news/viva-biotech-announces-2024-annual-results-significantly-rebounding-in-performance-with-new-stage-ahead-ai-leads-to-a-new-era-of-novel-drug-randd</link>
<guid isPermaLink="true">https://6ix.com/company/viva-biotech-holdings/news/viva-biotech-announces-2024-annual-results-significantly-rebounding-in-performance-with-new-stage-ahead-ai-leads-to-a-new-era-of-novel-drug-randd</guid>
<pubDate>Thu, 27 Mar 2025 13:35:00 GMT</pubDate>
<description>On March 27, 2025, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue during the Reporting Period achieved RMB1,986.7 million, gross profit amounted to RMB687.4 million and net profit recorded RMB222.0 million, a significant turnaround from a net loss of RMB99.8 million in the corresponding period of last year, mainly benefiting from the elimination of relevant financial adjustments due to the full repayment of convert</description>
</item>
</channel>
</rss>